HRA-19a1.1, NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA., 09071517
biological source
human colon
packaging
tube of 5 μg 09071517-DNA-5UG pkg of vial of cells 09071517-1VL
The HRA-19 cell line was established from a primary human rectal adenocarcinoma present in a 66-year old male. The adenocarcinoma was well differentiated and determined to be Dukes′ stage B. The HRA-19a1.1 cell line is a clone of HRA-19. HRA-19 has stem cell properties and undergoes a multilineage differentiation in serum free medium.
Split sub-confluent cultures (70-80%) 1:5 to 1:6 weekly using 0.05% trypsin/EDTA; 7.5% CO2; 37 °C. Suggested seeding density 2-4x10,000 cells/cm2.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Disclaimer
This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
